Advancing Botanical Drug Development Act of 2026

The Advancing Botanical Drug Development Act of 2026 extends the market exclusivity period for new FDA-approved botanical drugs from five years to twelve years. This change directly affects pharmaceutical companies and other sponsors that develop plant-based medicines, providing them with a longer window of protection against generic competitors. The bill aims to offset the high costs and unique manufacturing challenges associated with developing these complex therapies by offering stronger financial incentives. By securing this extended exclusivity, the legislation seeks to encourage private investment in research for multi-target treatments of chronic and age-related diseases.